AI assistant
Sending…
Entera Bio Ltd. — Director's Dealing 2022
Sep 9, 2022
35604_dirs_2022-09-09_85e1b9df-9e64-4d45-a4c1-ae0885aedc2e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2022-09-07
Reporting Person: Yaacov-Garbeli Dana (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-09-07 | Stock Option (right to buy) | $2.86 | A | 35000 | Acquired | 2031-03-31 | Ordinary Shares, par value NIS 0.0000769 per share (35000) | Direct |
Footnotes
F1: This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
More from Entera Bio Ltd.
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
Mar 25
Regulatory Filings
2026
Mar 4
Director's Dealing
2026
Feb 17
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 9